Avita Medical (RCEL) to Release Earnings on Thursday

Avita Medical (NASDAQ:RCEL) is expected to post its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Avita Medical to post earnings of ($0.36) per share and revenue of $26.27 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Avita Medical (NASDAQ:RCEL) last posted its earnings results on Thursday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). The business had revenue of $17.06 million for the quarter, compared to analyst estimates of $29.39 million. On average, analysts expect Avita Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Avita Medical Stock Down 5.1%

Shares of NASDAQ RCEL opened at $4.08 on Thursday. The firm’s 50-day moving average price is $3.68 and its 200-day moving average price is $4.38. Avita Medical has a 52-week low of $3.22 and a 52-week high of $11.25. The company has a market cap of $124.40 million, a PE ratio of -2.25 and a beta of 1.78.

Analysts Set New Price Targets

RCEL has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Avita Medical in a report on Monday, December 29th. D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Avita Medical in a report on Monday, January 26th. Zacks Research raised Avita Medical from a “strong sell” rating to a “hold” rating in a report on Friday, December 19th. BTIG Research raised Avita Medical from a “sell” rating to a “neutral” rating in a report on Thursday, November 20th. Finally, Lake Street Capital raised their target price on Avita Medical from $3.00 to $3.50 and gave the stock a “hold” rating in a research report on Friday, January 16th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Institutional Trading of Avita Medical

Several hedge funds have recently bought and sold shares of the stock. Bridgeway Capital Management LLC increased its position in Avita Medical by 213.8% in the third quarter. Bridgeway Capital Management LLC now owns 118,004 shares of the company’s stock worth $603,000 after buying an additional 80,404 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Avita Medical in the 1st quarter worth approximately $799,000. Jane Street Group LLC raised its stake in Avita Medical by 36.1% during the 2nd quarter. Jane Street Group LLC now owns 86,730 shares of the company’s stock worth $459,000 after acquiring an additional 22,986 shares during the period. Bank of America Corp DE raised its stake in Avita Medical by 49.7% during the 2nd quarter. Bank of America Corp DE now owns 62,551 shares of the company’s stock worth $331,000 after acquiring an additional 20,767 shares during the period. Finally, Brooklyn Investment Group lifted its holdings in Avita Medical by 48,965.5% during the third quarter. Brooklyn Investment Group now owns 58,388 shares of the company’s stock valued at $298,000 after purchasing an additional 58,269 shares in the last quarter. Institutional investors own 27.66% of the company’s stock.

About Avita Medical

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.